Psoriasis Market Poised for Robust Growth Driven by Biologics, Biosimilars, and Personalized Therapies – BIS Research

What Is Psoriasis? 

Psoriasis is a chronic autoimmune disorder in which the immune system accelerates the production of skin cells, leading to scaly, inflamed patches. The condition varies in severity, sometimes extending to the joints as psoriatic arthritis. Beyond its physical effects, psoriasis can significantly impact emotional well-being and quality of life. Recent progress in diagnostics, such as biomarker testing and advanced imaging, has enhanced accuracy in detection and disease monitoring. 

What Is the Market Outlook?

• Therapeutic Growth: Increasing adoption of biologics, interleukin inhibitors, TNF inhibitors, JAK inhibitors, and biosimilars. 
• Personalized Medicine: Rising emphasis on genetic and immune-profiling approaches for individualized treatment. 
• Pipeline Strength: Robust research pipelines backed by major pharmaceutical players. 
• Regional Expansion: Greater market penetration in emerging economies with improved healthcare infrastructure and higher diagnosis rates. 

How Fast Is the Market Growing? 

The psoriasis market is expanding steadily, supported by factors such as rising prevalence of autoimmune diseases, broader access to advanced treatments, and favorable reimbursement policies across key geographies. 

How Will This Report Help You? 

• Planning to Enter the Market? 
• Identify opportunities across biologics, biosimilars, and topical therapies. 
• Analyzing the Competitive Landscape? 
• Review strategies from AbbVie, Amgen, Novartis, Eli Lilly, Johnson & Johnson, and others. 
• Seeking R&D Insights? 
• Track developments in interleukin inhibitors, JAK inhibitors, and next-generation monoclonal antibodies. 
• Interested in Regional Market Trends? 
• Understand adoption drivers, pricing strategies, and regulatory frameworks across major markets. 

Download the Full TOC or Book a Preview 

What Technologies Are Transforming the Market? 

• Biologic Therapies (TNF inhibitors, IL-17 and IL-23 inhibitors) 
• Oral Small Molecules (JAK inhibitors, PDE4 inhibitors) 
• Innovative Topical Formulations (steroid-sparing and novel compounds) 
• Biosimilars Driving Affordability and Access 
• Biomarker-Based Diagnostics and Imaging Tools 

What’s Driving Demand, Opportunities, and Barriers? 

Demand Drivers 

• Increasing incidence of psoriasis globally 
• Advancements in targeted therapies and biologics 
• Improved awareness and early diagnosis 

Opportunities 

• Growth of biosimilars in cost-sensitive markets 
• Expansion of personalized medicine approaches 
• Rising demand for oral and non-invasive therapies 

Challenges 

• High treatment costs limiting access 
• Limited availability of advanced options in some regions 
• Variability in patient response to therapies 

Market Segmentation 

By Drug Class: 

• Interleukin Inhibitors 
• TNF Inhibitors 
• Others 

By Route of Administration: 

• Oral 
• Parenteral 
• Topical 

By Region: 

• North America (U.S., Canada) 
• Europe (U.K., Germany, France, Italy, Spain, Rest of Europe) 
• Asia-Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific) 
• Rest of the World (Latin America, Middle East & Africa) 

Key Players 

• AbbVie 
• Amgen Inc. 
• AstraZeneca 
• Boehringer Ingelheim 
• Eli Lilly and Company 
• Evelo Biosciences, Inc. 
• Johnson & Johnson 
• LEO Pharma A/S 
• Merck & Co., Inc. 
• Viatris 
• Novartis AG 
• Pfizer Inc. 
• Sanofi 
• UCB S.A. 

Strategic Developments 

• Expansion of biologic and targeted therapy pipelines 
• Collaborations between pharma and diagnostic companies for biomarker-based treatments 
• Growing investments in biosimilars to improve affordability and global reach 

Download the Complete TOC Now! 

Case Study 

The report highlights how novel interleukin inhibitors and JAK inhibitors are transforming treatment outcomes by improving efficacy and patient quality of life. Biosimilars are further creating opportunities by enhancing affordability and access, especially in emerging markets. 

Schedule a Call with Industry Experts  

Related Reports from BIS Research  

Hepatic Encephalopathy Market 

Presbyopia Market 

Hypoxic Ischemic Encephalopathy Market 

About BIS Research  

BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends, which can disrupt the market dynamics in the near future. We publish over 200 market intelligence studies annually, focusing on several deep technology verticals.    

Our strategic market analysis emphasizes market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.     

BIS Research offers syndicate and custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscapes.    

Contact  

Head of Marketing   

Email: media@bisresearch.com     

BIS Research Inc.    

39111 PASEO PADRE PKWY STE 313,    

FREMONT, CA 94538-1686   

Visit our Blog @https://bisresearch.com/insights    

Get Expert Insights @https://community.insightmonk.com     

Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research     

Connect with us on Twitter@ https://twitter.com/BISResearch    

Connect with us on Medium@ https://medium.com/@faisal.bis  

Connect with us on youtube@ https://www.youtube.com/@BISResearchInc